GLUE

Monte Rosa Therapeutics

GLUE

Attention (50-day avg)0%

Attention rank (50-day avg)#2,025

Bullish sentiment (50-day avg)58%

Price to earnings ratio49.2

Market capitalization999M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)123.7M

Net income (annual)-38.6M

Monte Rosa Therapeutics, Inc.

Healthcare
Biotechnology

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs. The company’s research is centered on precision medicine approaches that combine chemistry, structural biology, proteomics, and computational methods to identify and optimize novel therapies. Monte Rosa Therapeutics, Inc. operates in the biotechnology sector, where targeted protein degradation is an important area of drug discovery and development.

Website

Location

321 Harrison Avenue

Boston, MA, 02118

United States

#	Name	Attention
1	Alumis Inc.ALMS	0%0
2	Kymera Therapeutics Inc.KYMR	0%0
3	Erasca Inc.ERAS	0%0
4	VTYX - Ventyx Biosciences, Inc.	——
5	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
6	Global Interactive Technologies, Inc.GITS	0%0
7	AXIL Brands, Inc.AXIL	0%0
8	Arvinas, Inc.ARVN	0%+0
9	4D Molecular Therapeutics, Inc.FDMT	0%new
10	Crinetics Pharmaceuticals IncCRNX	0%new

Social

What share of all stock conversation is about GLUE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 31

Monte Rosa Therapeutics, Inc.'s (GLUE) stock price plummeted 32% following Novo Nordisk's (NVO) ZEUS setback, which saw the failure of ziltivekimab in the phase 3 trial.
GLUE's degrader, MRT-8102, has a chance to succeed regardless of the NVO failure, as it targets a different pathway and has shown promising results in stimulated human macrophage-derived cells (hMDM).
GLUE's stock price may continue to be affected by tax loss selling, with a predicted range for the year of $10-$30, and some investors may consider re-entering the stock at current levels due to its undervalued status.

Generated by AI

Sentiment

Of the messages about GLUE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.03% +3.82
Bearish	—	—	—	9.97% -3.82

Bullish· Jan 8

Monte Rosa Therapeutics' proposed public offering has triggered a significant price surge in GLUE, breaking resistance and fueling momentum.
The company's strong Phase 1 data showing reduction in inflammation markers has driven biotech momentum and contributed to the price increase.
GLUE's institutional ownership is high, with a significant portion of shares owned by rutes, limiting the supply of shares available for short selling.

Bearish· Jan 7

$GLUE is likely to experience a significant price drop, potentially even a 300% decline.
The company's small float size (25%) may lead to a short squeeze, further exacerbating the price decline.
$GLUE's current trend is downward, and a break below its major trendline and IPO resistance could lead to a price drop to $30 or lower.

Generated by AI

Topics

Of the messages about GLUE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.97%
Technical Analysis	—	—	0%	12.31%
Controversies	—	—	0%	0.62%
Analysts	—	—	0%	4.41%
Earnings	—	—	0%	1.03%
Macro	—	—	0%	2.67%

Announcements· Jan 7

Monte Rosa Therapeutics, Inc. announced positive interim Phase 1 data for MRT-8102, showing an 85% median hsCRP reduction with favorable safety in elevated cardiovascular risk subjects.
The company is planning a public offering of $200M worth of common stock and pre-funded warrants to purchase shares of common stock.
Monte Rosa Therapeutics has a global license and collaboration agreement with Novartis for the development and commercialization of certain programs, including MRT-8102 and a VAV1-directed molecular glue degrader.

Technical Analysis· Jan 7

$GLUE is trading near a major trendline and IPO resistance, with a potential break leading to a price of $30.
The stock has a clean break and no gaps, with a possible continuation above $25, but requires confirmation to keep going.
$GLUE is forming a clean cup and handle pattern just under $23.79, with volume expected to confirm if the handle starts to curl.

Generated by AI

Community

Of the messages about GLUE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	56.76%	28.6%
Newcomers	—	—	43.24%	71.4%

Regulars· Jan 7

Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim Phase 1 data for MRT-8102, showing an 85% reduction in CRP levels in CVD-risk subjects, with 94% of participants achieving CRP levels below 2 mg/L.
The company is targeting large markets with VAV1 and NEK7, with the potential to disrupt the dominance of biologics and JAKs/TYK2 inhibitors.
GLUE has announced plans for a Phase 2 study in ASCVD for 2026, following the positive Phase 1 results, and has also commenced a public offering of $200.0 million of common stock and pre-funded warrants.

Newcomers· Jan 8

Newcomers to the stock are excited about the positive interim Phase 1 clinical data released by Monte Rosa Therapeutics, showing its lead drug candidate significantly reduced inflammation markers.
The asset's price has been affected by the announcement of a $2 billion common stock and pre-funded warrant offering, but the market reaction has been muted, leading some to speculate that the clinical data may be too strong.
The stock has been experiencing high volume and has seen significant price increases, with some attributing the movement to the gap up and volume on the day prior to the announcement, as well as buyout rumors.

Generated by AI

Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc.

Company Information

Location

Monte Rosa Therapeutics

Social

Jul 31

Bullish· Jan 8

Bearish· Jan 7

Announcements· Jan 7

Technical Analysis· Jan 7

Regulars· Jan 7

Newcomers· Jan 8

Monte Rosa Therapeutics: Ziltivekimab's Failures, Additional Thoughts On MRT-8102 And MRT-6160 (NASDAQ:GLUE)

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet (NASDAQ:GLUE)

Also Discussed

Monte Rosa Therapeutics, Inc.

Company Information

Location

Social

Jul 31

Bullish· Jan 8

Bearish· Jan 7

Announcements· Jan 7

Technical Analysis· Jan 7

Regulars· Jan 7

Newcomers· Jan 8

Monte Rosa Therapeutics: Ziltivekimab's Failures, Additional Thoughts On MRT-8102 And MRT-6160 (NASDAQ:GLUE)

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet (NASDAQ:GLUE)

Also Discussed